|
Title
|
Published
|
Price
|
|
China Pharma Outsourcing Annual Review 2009
By: JZMed, Inc.
It has been well recognized that 2009 is a rough year to all types of industries worldwide. The financial crisis has significantly altered both pharmaceutical and biotechnology industries on global scale. The pharma
|
more...
|
11/1/2009
|
$1,385.00
|
|
Asia Pacific Pharma Sector Analysis
By: RNCOS
The world continues to witness significant shift in the global pharmaceutical market landscape, with Asia-Pacific emerging as the fastest growing pharmaceutical market over the recent past. With low costs and favorable regulatory environment, the region
|
more...
|
11/1/2009
|
$1,200.00
|
|
BI for Drug Development: Oracle Introduces Clinical Development Analytics
By: IDC
This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical
|
more...
Search inside this report
|
11/1/2009
|
$1,500.00
|
|
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
By: Datamonitor
Introduction CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there
|
more...
|
10/21/2009
|
$11,400.00
|
|
Notable News in the Life Sciences: 3Q09
By: IDC
This Health Industry Insights Perspective provides an unranked list and assessment of important news and trends reported in July through September 2009. (Note also that progress attained or subsequent news reported after the initial announcement
|
more...
Search inside this report
|
10/18/2009
|
$1,500.00
|
|
Pharmaceuticals Wholesaling in Australia - Industry Risk Rating Report
By: IBISWorld
Industry Risk Ratings Synopsis This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Pharmaceuticals Wholesaling in Australia industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business
|
more...
Search inside this report
|
10/17/2009
|
$810.00
|
|
Patent Foramen Ovale Closure Market: Clinical Trial Outcomes to Play a Key Role
By: GlobalData
Summary Over the last decade there has been considerable evidence gathered, relating Patent Foramen Ovales (PFO) to migraines, cryptogenic stroke and decompression sickeness. There is an increased frequency of PFO in patients suffering from migraine- a
|
more...
|
10/12/2009
|
$500.00
|
|
Orphan Drug Strategies
By: Datamonitor
Introduction With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now looking towards the development and commercialization of more niche, high value, often biologic therapies, for the treatment of
|
more...
|
10/2/2009
|
$3,800.00
|
|
Diabetes R & D Pipeline: PPAR Agonists
By: BioPolaris
Diabetes is a chronic disease that may reduce life expectancy by as much as 15 years because high blood
glucose levels can damage blood vessels and nerves. The International Diabetes Institute (Australia) estimates
that direct
|
more...
Search inside this report
|
10/1/2009
|
$650.00
|
|
Innovative Drug R&D in China
By: JZMed, Inc.
As Chinese pharmaceutical industry is rising rapidly, a growing number of Chinese drug companies pay attention to investing in research of innovative medicines. Their attempts are encouraged by government who promises to provide financial
|
more...
|
10/1/2009
|
$2,895.00
|
|
Cardiovascular Outlook: Pharmaceutical, Medical Device, New Technologies - Past, Present, and Future
By: Canon Communications, LLC
Cardiovascular disease is the leading cause of death in the United States, affecting an estimated 80.7 million American adults, with estimated treatment costs of more than $313.8 billion annually. This report contains qualitative analysis of
|
more...
|
10/1/2009
|
$535.00
|
|
Contract Pharmaceutical Manufacturing, Research and Packaging
By: BCC Research
REPORT HIGHLIGHTS
Overall sales in the pharmaceutical contract manufacturing and contract research market were worth nearly $143 million in 2007, which increased to an estimated $177 million in 2009. By 2014, sales are
|
more...
Search inside this report
|
10/1/2009
|
$4,850.00
|
|
The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
By: Kalorama Information
The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness
|
more...
|
10/1/2009
|
$3,500.00
|
|
The World Market for Addiction Disorders, 2009 - 2016
By: Spectra Intelligence
The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development
|
more...
Search inside this report
|
10/1/2009
|
$2,345.00
|
|
Diabetes R & D Pipeline: GLP-1 Agonists, Analogs and Allosteric Modulators
By: BioPolaris
The worldwide market for anti-diabetic therapeutic products is large and highly competitive. The global antidiabetic market is estimated to be over $24 billion in 2008. The largest players in this market are AstraZeneca plc (UK),
|
more...
Search inside this report
|
10/1/2009
|
$950.00
|
|
China: A New Era of Innovation in Drug Development
By: CenterWatch
In the latest edition from our Clinical Trials Special Report Series, we break down China’s clinical trials landscape and analyze the government investments and reforms that are making the country more attractive for inclusion in
|
more...
|
10/1/2009
|
$295.00
|
|
The Evolving Life Science Researcher - At the Cusp of Transformation
By: IDC
This Health Industry Insights Perspective highlights past researcher best practices and future expectations for the changing role of the individual researcher in the life science industry as companies and their researchers incrementally adapt to help
|
more...
Search inside this report
|
9/28/2009
|
$1,500.00
|
|
The Recession and its impact on Pharamceutical M&A Activity
By: Espicom Healthcare Intelligence
Expert analysis and detailed case histories illuminate the effect on, and activities of, pharmaceutical companies in the current economic downturn.
|
more...
Search inside this report
|
9/25/2009
|
$940.00
|
|
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment?
By: Decision Resources
Introduction
“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many
sarcoidosis patients require little or no treatment, but patients with chronic disease need a
|
more...
|
9/23/2009
|
$4,500.00
|
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
By: Decision Resources
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as
creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses
|
more...
|
9/18/2009
|
$2,250.00
|
|
Disruption or Advantage? Update on Companion Diagnostics
By: Decision Resources
Introduction
Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders.
Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development
is huge because companion
|
more...
|
9/15/2009
|
$2,250.00
|
|
Medical Research Key Recent Media Coverage, Second Quarter 2009
By: TecTrends Reporter
Important and interesting medical discoveries are being made everyday. From innovations in stem cell research and bioengineering to cutting-edge treatments for major diseases and new insights into wellness, the world of medicine is constantly
|
more...
|
9/15/2009
|
$179.95
|
|
Biomarkers- Advanced Technologies and Global Market (2009-2014)
By: MarketsandMarkets
Report Description
The Global Biomarker Market report analyzes the biomarker tools and services market over the period 2009-2014. The report studies the major market drivers, restraints, and opportunities for the global biomarker market; and
|
more...
Search inside this report
|
9/9/2009
|
$4,650.00
|
|
Global Economic Downturn: Implications for the Pharmaceutical Industry
By: Business Monitor International
From A Credit Crunch… Following several decades of multilateral efforts to ensure good governance within emerging markets to reduce economic volatility, it is no small irony that the credit crisis originated in the US, the heart
|
more...
Search inside this report
|
9/8/2009
|
$865.00
|
|
Ion Channel Modulator Pipelines: Targets and Agents in Development
By: CHI Insight Pharma Reports
Ion channels represent a significant opportunity to address an underexploited class of therapeutic targets. Nearly 150 novel ion channel modulators are reported to be in clinical development. This report examines:
Ion channel modulators in
|
more...
|
9/1/2009
|
$3,750.00
|
|
Title
|
Published
|
Price
|
(0 items)
